ARTICLES

The pharmaceutical industry is evolving rapidly, with increasing regulatory demands, complex drug formulations, and the rise of biologics challenging traditional manufacturing methods. <br> How can companies stay ahead while ensuring efficiency, quality, and compliance? <br><br> This white paper delves into Quality by Design (QbD) and Design of Experiments (DoE)—two transformative methodologies that are revolutionising drug development. <br><br> Learn how top pharmaceutical companies like Strides Pharma leverage these approaches to enhance product quality, reduce risks, optimise processes, and streamline regulatory compliance. <br><br> Get insights on: <br> ✔️ QbD’s shift from reactive testing to built-in quality <br> ✔️ DoE’s role in faster, smarter drug formulation <br> ✔️ A real-world case study on arthritis medication development <br>

Everyone sees the product launch. Few see the decisions that made it possible.

The game-changer for sustained growth

Set to skyrocket from $367.1 billion in 2023 to $628 billion by 2032, the generic drug market is experiencing a boom! What's fueling this rapid expansion? A mix of factors: patent expirations, a rise in chronic diseases, and increased research investments.

Enters S&P yearbook in 1st year of participation

The pharmaceutical industry is facing an alarming trend: a dramatic increase in drug recalls. In 2022 alone, defective pharmaceutical units hit a five-year high, with January 2023 marking a significant spike in recalls– over 11.88 million units impacted due to critical deviations from Good Manufacturing Practices (GMP).